Clinical Trials Logo

Clinical Trial Summary

This study will examine the types of bacteria present in the dental plaque of patients with persistent dry mouth. Saliva is essential for digestion and swallowing and for maintaining the normal mineralization of teeth. People who suffer from dry mouth usually have a significant increase in tooth decay (caries). This study will determine if this increase is due solely to reduced salivary flow or also to an increase in certain types of bacteria in the mouth.

Patients participating in the following NIDCR protocols may be eligible for this study: Evaluation and Treatment of Salivary Dysfunction (84-D-0056), Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome Research Project (99-D-0070), and Salivary Evaluation in Normal Volunteers (94-D-0018).

Participants will have three appointments at the NIH dental clinic as follows:

Visit 1

Dental examination and instruction on keeping a detailed diary of food intake.

Visit 2 (1 week after visit 1)

Attachment of a bacteria collection device (described below) to the side of a tooth.

Visit 3 (48 hours after visit 2)

Removal of the collection device, tooth cleaning and polishing, and submission of food diary.

The bacteria collection device is a 4mm x 2mm x 2mm square of sterilized tooth obtained from slicing an extracted healthy tooth donated by another patient. The donated teeth are either extracted impacted third molars (wisdom teeth) or teeth extracted for teeth straightening (orthodontics). The device is heat-sterilized before being bonded to the participant's tooth. The dental cement used for bonding can be removed after 48 hours with no damage to the surface of the participant's tooth.


Clinical Trial Description

Although significant improvements have been made in the dental health status of the US population, dental caries remains a significant problem. The most recent Surgeon General's Report (2000) noted that 20% of the US population bears 60% of the caries burden. Caries incidence is even higher in children of minorities, the chronically ill, the physically handicapped, the elderly and the institutionalized.

Dental Caries is a multi-factorial disease in which the fermentation of dietary carbohydrate by oral bacteria results in acid dissolution of tooth structure. Important risk factors include the frequency of dietary carbohydrate intake, intra-oral plaque levels, the levels of cariogenic oral bacteria, salivary insufficiency and past fluoride exposure.

A medical condition shown to be associated with increased caries risk and caries incidence is Sjogren's syndrome (Kolavic et al 1997, Pedersen et al 1999, Almstahl et al 1999). Sjogren's syndrome (SS) predominantly affects women and is an auto-immune disorder characterized by an epitheliitis or exocrinopathy. Both primary and secondary forms are described. Secondary SS sees the condition co-exist with other auto-immune disease such as rheumatoid arthritis (See reviews by Fox and Maruyama 1997, Fox et al 1999, Pflugfelder 1998 )

A recent study by Sreebny and Zhu (Adv. Dent Res 1996), demonstrated that individuals with a diagnosis of SS are nearly 40% more likely to harbor high levels of the species Lactobacillus in plaque and saliva than healthy individuals. LB has been shown in to be a major etiological agent in dental caries progression.

The principal hypothesis of this study is that SS patients are at a higher risk of caries development not just because of reduced salivary flow (xerostomia) but also changes in the output of organic and inorganic microbial regulatory components in saliva secondary to their auto-immune disease. These alterations favor a selective increase in the proportion of cariogenic microflora in plaque located on their teeth. Specifically, mutans streptococci (MS) and Lactobacillus (LB) species are increased in frequency and number in SS patients compared with xerostomic patients with no detectable auto-immune disease.

The proposed study will investigate microbial counts of MS and LB in the plaque of patients with a clinical diagnosis of markedly reduced salivary flow (pooled unstimulated flow &eq; 0.1 ml/min). All clinical procedures will take place at NIH. Some samples and all data, without any patient identifiers, will be analyzed outside.

Plaque samples will be collected from sites identified to be at high-risk for caries initiation and development. It is generally accepted that discernment of microbial etiology is blunted by using salivary or pooled plaque monitoring of MS and LB as a surrogate for samples of plaque in areas of high caries risk. This is supported by current knowledge of the biology of MS/LB and expected locations of carious lesions.

Saliva samples will not be collected due to difficulties in obtaining sufficient fluid as a result of the concurrent xerostomia.

The proposed study will examine the relationship between MS/LB and reduced salivary flow in two patient groups:

1. A patient group with reduced salivary flow AND a diagnosis of primary or secondary SS (as per the Revised International Criteria for diagnosis of SS) OR auto-immune disease of non-SS etiology.

2. A non-disease control group, who do not meet the criteria for SS, with reduced salivary flow AND who have suffered subjective symptoms of xerostomia or xerophthalmia for a period longer than 6 months OR who are taking medication with xerogenic effect.

Plaque micro-organisms will be harvested from a "collection device" bonded to the surface of a posterior tooth shown to be at high risk for caries development. Plaque collected in this way has been shown to closely simulate the complex ecology of a mature cariogenic plaque. The harvested organisms will then be plated on non-selective media for enumeration of total microbial load and on selective media for enumeration of specific cariogenic bacteria.

More comprehensive knowledge of the effect of SS on microbial flora in different predeliction sites for oral diseases would be of great value for effective treatment planning in SS and for the evaluation of the effect of oral treatments and of preventive measures implemented in individuals with SS. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00048685
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date November 2002
Completion date August 2004

See also
  Status Clinical Trial Phase
Recruiting NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Completed NCT03266172 - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Phase 1
Completed NCT03649412 - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Phase 1
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT00975936 - Phase 0 Microdose Study Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01210716 - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Phase 3
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Withdrawn NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Recruiting NCT06019611 - Epidural Stimulation in Multiple Sclerosis N/A
Recruiting NCT05030779 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Early Phase 1
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Recruiting NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 Phase 1